← All trials
NCT06463457
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Nov 30, 2028
- Completion date
- Nov 30, 2028
- First posted
- Jun 17, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 33
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOfficial
- SumitomoCollaborator
- PfizerCollaborator
- BayerCollaborator
- Harvard UniversitySponsor investigator
- National Comprehensive Cancer NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.